JasonCChandlerMD

Oncology • Germantown, TN

Assistant Professor, Medicine-Hematology, University of Tennessee Health Science Center College of Medicine

Join to view full profile

Dr. Chandler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chandler's full profile

Already have an account?

Office
7945 Wolf River Blvd
Germantown, TN 38138
Phone+1 901-683-0055

Fax+1 901-685-9718
Is this information wrong?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2009
University of TennesseeResidency, Internal Medicine/Pediatrics, 2003 - 2007
University of Tennessee Health Science Center College of MedicineClass of 2003

Certifications & Licensure

TN State Medical License 2006 - 2025
MS State Medical License 2010 - 2024
AR State Medical License 2012 - 2024
OH State Medical License 2007 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017

Clinical Trials

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3

Publications & Presentations

PubMed

Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.
Andres Forero-Torres, Jason Claud Chandler, Swaminathan P Iyer, Abraham S Kanate, Michelle Quinlan, Petra Hoever, Miguel Izquierdo, Jaclyn Davis, Sumit Madan> ;Clinical Pharmacology in Drug Development. 2022 Sep 1
4 citations
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Vincent Ribrag, Julio C Chavez, Carola Boccomini, Jason Kaplan, Jason C Chandler, Armando Santoro, Paolo Corradini, Ian W Flinn, Ranjana Advani, Philippe A Cassier, Ra...> ;Ejhaem. 2022 Feb 1
25 citations
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, o...
Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder...> ;The Lancet. Haematology. 2021 Apr 1
6 citations
TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients.
Ritu Pandey, Nathan Johnson, Laurence Cooke, Benny Johnson, Yuliang Chen, Manjari Pandey, Jason C. Chandler, Daruka Mahadevan> ;Cancers. 2021 Feb 3
152 citations
Multiple myeloma, version 3.2021
Shaji Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Erica L. Campagnaro, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Y...> ;Journal of the National Comprehensive Cancer Network. 2020 Dec 2
91 citations
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
David M. Waterhouse, Edward B. Garon, Jason C. Chandler, Michael McCleod, Maen A. Hussein, Robert M. Jotte, Leora Horn, Davey B. Daniel, George P. Keogh, Ben C. Creela...> ;Journal of Clinical Oncology. 2020 Sep 10
124 citations
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including...
David R. Spigel, Michael McCleod, Robert M. Jotte, Lawrence H. Einhorn, Leora Horn, David M. Waterhouse, Ben C. Creelan, Sunil Babu, Natasha B. Leighl, Jason C. Chandl...> ;Journal of Thoracic Oncology. 2019 Sep 1
58 citations
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David S. Hong, Drew W. Rasco, Michael H. Veeder, Jason J. Luke, Jason C. Chandler, Ani Sarkis Balmanoukian, Thomas J. George, Pamela N. Munster, Jordan Berlin, Martin ...> ;Oncology. 2019 Jan 1
2 citations
Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
Brennan McCullar, Manjari Pandey, George Yaghmour, Felicia Hare, Kruti Patel, Matthew K Stein, Rebecca Feldman, Jason C. Chandler, Michael Gary Martin> ;Breast Cancer Research and Treatment. 2019 Jan 1
11 citations
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Noelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R. Infante, Jason C. Chandler, Andrew Weickhardt, Jason D. Lickliter, John Sarantopoulos, Michael S. Gordon, Gabriel Mak,...> ;British Journal of Clinical Pharmacology. 2018 Apr 1
170 citations
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advance...
David R. Spigel, Craig W. Reynolds, David M. Waterhouse, Edward B. Garon, Jason C. Chandler, Sunil Babu, Paul Thurmes, Alexander I. Spira, Robert M. Jotte, Jin Zhu, We...> ;Journal of Thoracic Oncology. 2018 May 1
13 citations
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
David M. Waterhouse, Leora Horn, Craig H. Reynolds, David R. Spigel, Jason C. Chandler, Tarek Mekhail, Mohamed K. Mohamed, Ben C. Creelan, Kenneth B. Blankstein, Petro...> ;Cancer Chemotherapy and Pharmacology. 2018 Feb 13
108 citations
Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines
Shaji Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jorge J. Castillo, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henr...> ;Journal of the National Comprehensive Cancer Network. 2018 Jan 1
231 citations
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-la...
James L. Gulley, Arun Rajan, David R. Spigel, Nicholas Iannotti, Jason C. Chandler, Deborah J.L. Wong, Joseph Leach, W. Jeff Edenfield, Ding Wang, Hans Juergen Grote, ...> ;The Lancet. Oncology. 2017 May 1
211 citations
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Shaji Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Cristina...> ;Journal of the National Comprehensive Cancer Network. 2017 Feb 1
5 citations
Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality.
Philippe Prouet, Smith Giri, Eric Wiedower, Andrew Fintel, George Yaghmour, Elena P. Lamb, Jeremiah L. Deneve, Martin D. Fleming, Paxton V. Dickson, Jason C. Chandler,...> ;Anticancer Research. 2017 Feb 1
9 citations
Genomic alterations in neuroendocrine cancers of the ovary
George Yaghmour, Philippe Prouet, Eric Wiedower, Omer Jamy, Rebecca Feldman, Jason C. Chandler, Manjari Pandey, Michael Gary Martin> ;Journal of Ovarian Research. 2016 Aug 26
23 citations
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
Brennan McCullar, Manjari Pandey, George Yaghmour, Felicia Hare, Kruti Patel, Matthew K Stein, Rebecca Feldman, Jason C. Chandler, Michael Gary Martin> ;Breast Cancer Research and Treatment. 2016 Jun 21
3 citations
Unusual, spontaneous aneurysm formation in a patient being treated with ibrutinib for chronic lymphocytic leukemia.
Eric Wiedower, Felicia Hare, Adam S Arthur, Jason C. Chandler, Michael Gary Martin> ;Therapeutic Advances in Hematology. 2016 May 17
2 citations
Treatment Disparities Faced by Undocumented Workers From Low- and Middle-Income Countries in the United States With Hematologic Malignancies.
Sara Nunnery, Andrew E. Fintel, W. Clay Jackson, Jason C. Chandler, Michael O. Ugwueke, Michael Gary Martin> ;Journal of the National Comprehensive Cancer Network. 2016 Apr 1
51 citations
NCCN guidelines® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelines
Kenneth C. Anderson, M. Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, ...> ;Journal of the National Comprehensive Cancer Network. 2016 Apr 1
7 citations
Comorbidities Drive Outcomes for Both Malignancy-Associated and Non–Malignancy-Associated Hemophagocytic Syndrome
Benny Johnson, Smith Giri, Sara Nunnery, Eric Wiedower, Omer Jamy, George Yaghmour, Jason C. Chandler, Michael Gary Martin> ;Clinical Lymphoma, Myeloma & Leukemia. 2015 Dec 3
86 citations
Multiple myeloma, version 2.2016: Clinical practice guidelines in oncology
Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gaspare...> ;Journal of the National Comprehensive Cancer Network. 2015 Nov 1
86 citations
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a po...
Il-Kyoo Park, Anjali Mishra, Jason C. Chandler, Susan P. Whitman, Guido Marcucci, Michael A. Caligiuri> ;Blood. 2013 Mar 14
123 citations
Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation
Anjali Mishra, Shujun Liu, Gregory H. Sams, Douglas P. Curphey, Ramasamy Santhanam, Laura J. Rush, Deanna M. W. Schaefer, Lauren G. Falkenberg, Laura Sullivan, Laura J...> ;Cancer Cell. 2012 Nov 13
Join now to see all